Italia markets close in 3 hours 10 minutes
FTSE MIB
32.851,03 +185,82 (+0,57%) Dow Jones
38.589,16 -57,94 (-0,15%) Nasdaq
17.688,88 +21,28 (+0,12%) Nikkei 225
38.102,44 -712,12 (-1,83%) Petrolio
78,76 +0,31 (+0,40%) Bitcoin EUR
61.309,47 -755,41 (-1,22%)
NBIX Nov 2024 160.000 call
OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
In data: 10:14AM EDT. Mercato aperto.
| Chiusura precedente | 8,00 |
| Aperto | N/D |
| Denaro | 5,10 |
| Domanda | 8,40 |
| Prezzo d'esercizio | 160,00 |
| Scadenza | 2024-11-15 |
| Min-Max giorno | 8,00 - 8,00 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 10 |
GlobeNewswireSosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat
© 2024 Yahoo. Tutti i diritti riservati.